Tolmar Affirms Full Supply of Eligard for Palliative Treatment of Prostate Cancer

Tolmar Affirms Full Supply of Eligard for Palliative Treatment of Prostate Cancer
Tolmar Pharmaceuticals maintains a complete inventory of Eligard (leuprolide acetate), its therapy for advanced prostate cancer, and had increased production in response to reports of shortages of other leuprolide acetate products in the U.S., the company announced. As of Aug. 25, the U.S. Food and Drug Administration listed three formulations of Lupron Depot (leuprolide acetate) as unavailable and/or on backorder for an unknown duration on the administration's drug shortage information database. "Tolmar is pleased to step up production in our state-of-the-art cGMP [Current Good Manufacturing Practice] facilities to help ensure that advanced prostate cancer patients across the U.S. won't miss a single injection in their treatment plan," Anil D'Souza, Tolmar's CEO, said in a press release. "Eligard has always been manufactured to the highest quality standards in our Northern Colorado plants, and we are able to fill any short or long-term gaps in the supply
Subscribe or to access all post and page content.